Progestin therapy for breast cancer: a panel discussion

The use of pharmacologic doses of steroid hormones to treat patients with advanced breast cancer has been standard for many years. Recently there has been increased interest in the investigation of progestational agents, largely as a result of their excellent response rate in selected patients and their minimal side effects. In this panel discussion the participants discuss the use of progestin in advanced and early breast cancer. Criteria for patient selection, such as receptor status or response to previous therapies, are analyzed, and dose-response relationship and the side effects are addressed.